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Background
Recombinant antibody mixtures represent an important
new class of antibody therapeutics as demonstrated by
the increasing amount of literature showing that combi-
nations of two or more antibodies show superiority
compared to monoclonal antibodies (mAbs) for treat-
ment of cancer and infectious diseases [1-5]. Sym004,
composed of two antibodies targeting non-overlapping
epitopes of the epidermal growth factor receptor (EGFR)
act in a synergistic manner to induce an efficient inter-
nalization of EGFR leading to subsequent degradation
and exhibit superior anticancer efficacy as demonstrated
in several preclinical in vivo models [5].
At Symphogen A/S, we have developed an expression
platform, Sympress™, for cost-efficient production of
antibody mixtures. The antibody mixtures are produced
using a single-batch manufacturing approach where a
polyclonal working cell bank (pWCB) prepared by mix-
ing the individual stable cell lines producing all the
desired antibodies is used as seed material for a bioreac-
tor process [6]. By using a single-batch approach the
CMC development costs of antibody mixtures are com-
parable to costs for monoclonal antibodies. However,
the single-batch manufacturing approach raises ques-
tions with regard to control of composition ratios, com-
positional stability and robustness of the cell banking
procedure.
Here, we present experimental data addressing these
key questions and demonstrate that mixtures of recom-
binant antibodies can be produced under predictable,
reproducible and stable conditions using the Sympress™
technology.
Material and methods
The second generation Sympress technology is based on
expression in the ECHO cell line, a genetically modified
version of the dihydrofolate reductase (DHFR) negative
Chinese Hamster Ovary (CHO) cell line DG44 [7].
The expression plasmid used for stable transfection
contained a bidirectional CMV promoter construct
enabling co-expression of the IgG light and heavy chains
from one plasmid. A DHFR selection marker was
coupled directly to the heavy chain via an internal ribo-
some entry site (IRES).
ECHO parental cells were transfected separately with
each of the individual antibody expression vectors using
standard transfection technology, whereafter cells were
subjected to a methotrexate (MTX) selection schedule.
The selected stable pools were single-cell cloned by
FACS and high-expressing clones were adapted to che-
mically defined cell culture medium, expanded and fro-
zen, still as individual monoclonal cell lines.
The preparation of polyclonal cell banks followed a
two-tiered cell banking approach. First, the relevant
monoclonal cell lines were thawed and expanded. They
were then mixed in predefined ratios and frozen as
polyclonal master cell banks (pMCB). The pMCB was
subsequently thawed, expanded and frozen as polyclonal
working cell bank (pWCB).
Antibody purification was performed by capture on a
MabSelect SuRe column and cation exchange chromato-
graphy (CIEX) was used to separate the different antibo-
dies based on their charge differences. The characteristics
of the chromatograms (peak area/peak height) were used
* Correspondence: skr@symphogen.com
Symphogen A/S, Elektrovej 375, 2800 Lyngby, Denmark
Full list of author information is available at the end of the article
Rasmussen et al. BMC Proceedings 2011, 5(Suppl 8):O2
http://www.biomedcentral.com/1753-6561/5/S8/O2
© 2011 Rasmussen et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Figure 1 A: Relative antibody ratios in pMCBs generated by mixing two ECHO cell lines at five different ratios. The antibody ratios were
determined once a week by CIEX (from week 1 to 6 of cultivation) and in the harvest of a 14-day fed batch cultivation initiated after 6 weeks of
cultivation. Red lines represent antibody 1 (Ab 1) and blue lines represent antibody 2 (Ab 2). B: Expected percentages plotted against measured
percentages of Ab 1 in the five different mixes after 6 weeks seed train. C: Antibody compositions in pWCB in fed batch shaker experiments
after 14, 21 and 28 days seed train, respectively. D:Antibody distributions in harvest from seven different 5 L bioreactor processes. Four pWCB-1
ampoules (blue columns) and three pWCB-2 ampoules (green columns) were used for seed train. The lighter colored columns represent mean ±
sdev.
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antibodies in the mixtures.
Results
Two ECHO cell lines producing two distinct antibodies
were selected based on their growth and production
characteristics for a study to examine how mixing of the
cells at different ratios affected the antibody composi-
tion. Briefly, the two cell lines were thawed, expanded
and mixed in five different rations (5:5; 4:6; 3:7; 2:8 and
1:9). The resulting mixtures were frozen as pMCBs. To
examine the obtained ratios and the compositional sta-
bility over prolonged periods of cultivation the pMCBs
were revived and subjected to six weeks cultivation in
shakers, followed by a 14 days fed batch process in sha-
kers. Supernatant samples were harvested once a week
and at the end of the fed batch process. IgG was cap-
tured by protein A and the relative antibody ratio was
determined by CIEX. The results clearly showed that all
the compositions were very stable over time and, impor-
tantly, that the relative amount of each antibody could
be controlled by mixing the cell lines in an appropriate
ratio (Figure 1A). Furthermore, the was a very strong
correlation (R2 = 0.997) between expected and mea-
sured percentage of Ab 1 as shown in figure 1B.
We then examined the compositional stability in a
more complex model composed of a mixture of six dif-
ferent antibodies. A seed train of approximately 3 weeks
would be required to generate cells for inoculation of
production reactors in a 10.000 L scaled-up manufactur-
ing process. To examine the robustness of the relative
cell compositions during this timeframe +/- one week the
cells from pWCB were inoculated into a 14 days fed
batch shaker after 14, 21 or 28 days of expansion, respec-
tively. The antibody distributions at the three different
time points were very constant as illustrated in Figure
1C. Additionally, the growth and production properties
were also very constant over time (data not shown).
The reproducibility and robustness of the cell banking
system was evaluated by comparing the antibody product
composition produced from two different pWCBs gener-
ated from the same pMCB. A pMCB producing a mix-
ture containing 6 antibodies was used for the study. We
generated two polyclonal working cell banks (pWCB-1
and pWCB-2) from the same pMCB. Production of
pWCB-2 was separated in time from production of
pWCB-1 by several months. Four ampoules from pWCB-
1 were expanded and used for inoculation of four 5 L
bioreactors for fed batch production. Several months
later, three ampoules from pWCB-2 were expanded and
used to perform three new 5 L bioreactor runs. The anti-
bodies were purified and antibody distribution deter-
mined by CIEX. The observed variation, both within the
same pWCB and between different pWCB in regard to
the antibody distributing was very limited (Figure 1D).
This strongly indication that the pMCB/pWCB concept
provides a reliable cell banking strategy. The reproduci-
bility was also confirmed with respect to cell growth and
productivity (data not shown).
Conclusion
Symphogen A/S has developed an expression platform,
Sympress™, that can be used for predictable, reproduci-
ble, and stable production of antibody mixtures in a
cost effective setting.
H e r e ,w eh a v es h o w nt h a tt h er e l a t i v ea n t i b o d yr a t i o
in antibody mixtures can be effective controlled using
appropriate mixing of the individual monoclonal cell
lines before generation of the pMCB. Further, we have
presented consistent data from fed batch productions
with pWCB where the seed train lengths varied from 14
to 28 days. This strongly supports that the single-batch
manufacturing concept is sufficiently robust for manu-
facturing, also at scales required for commercial manu-
facturing. The two-tiered cell bank approach composed
of pMCB and pWCB is robust and reproducible, and
showed very high consistency both within a given
pWCB and between different polyclonal working cell
banks generated from the same pMCB.
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